On April 27, 2021 Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, reported that it will present data detailing a new robotics technology to aid in multi-tumor-associated antigen (mTAA)-specific T cell therapy manufacturing at the upcoming American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) Annual Meeting, taking place virtually May 11-14, 2021 (Press release, Marker Therapeutics, APR 27, 2021, View Source;cell-therapy-asgct-annual-meeting-301278520.html [SID1234578589]). The data will be presented by lead author Anastasiya Smith, Ph.D.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation details how the robotic assistant prototype, co-designed by Marker Therapeutics and ABB Robotics, could in the future be integrated in a standard biosafety cabinet to collaborate with a human operator during mTAA-specific T cell manufacturing. The researchers found that the robotic assistant prototype was more precise and accurate than human operators in pipetting liquid and was more consistent in the number of cycles performed over a 1-hour test period, while the human operator’s performance deteriorated over time. The authors conclude that the future combination of process simplification with robotic automation may be able to address some of the challenges associated with cell therapy and make this therapy readily available to a larger patient population.
Presentation Details
Title: "Robotic Automation of T Cell Generation for the Treatment of Acute Myeloid Leukemia (AML)"
Authors: Anastasiya Smith, Ph.D., et al.
Session Type: Digital Poster Presentation
Session Date/Time: Tuesday, May 11, 2021, 8:00 a.m. – 10:00 a.m. ET
Session Title: Cell Therapies
Abstract: 772
The abstract is available on ASGCT (Free ASGCT Whitepaper)’s website and in an online supplement to the ASGCT (Free ASGCT Whitepaper) journal. The poster presentation will be available to ASGCT (Free ASGCT Whitepaper) registrants beginning May 11, 2021.